New President and CEO of AddLife

AddLife 01/09/2022

We are excited to announce, that as of today, we have a new CEO, Fredrik Dalborg. Fredrik is succeeding Kristina Willgård, our former CEO of seven successful years since AddLife started.

Fredrik Dalborg Linkedin

Fredrik joins us from his most recent role as Managing director of North America of XVIVO Perfusion. Fredrik is a well-qualified and business-oriented leader with international experience deeply rooted in Life Science.

“I have followed AddLife with great interest and am impressed with what the team has achieved under Kristina's leadership. The corporate culture and management philosophy that AddLife stands for is in line with my values and I am happy to be part of the AddLife team”, says Fredrik Dalborg, CEO of AddLife

We welcome Fredrik and look forward to working with him!

News from AddLife’s subsidiaries

Eriikka Varastossa Ivd 09 2022 1 768X403
05 October 2022
IVD Regulation improves patient safety

Implementing the requirements of the new EU Regulations improves patient safety and clarifies the responsibilities of the various operators in the distributor chain. Triolab has prepared for the regulatory reform for a long time.

Triolab OY
Sepsis. Main
04 October 2022
Ultra-rapid antibiotic susceptibility testing

Sepsis is a potentially life-threatening condition caused by the body‘s response to an infection. Prompt diagnosis, intervention, and risk assessment are essential in caring for sepsis.